Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Shenzhen Bioeasy Biotechnology Co. Ltd. stock ¥1.28, price ¥5.66, that is 77.4% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥5.66 – ¥40.06 · fair‑value band ¥0.8500 – ¥1.49 · the ¥5.66 price screens above the ¥1.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Shenzhen Bioeasy Biotechnology Co. in your weekly email
Every Wednesday you see whether Shenzhen Bioeasy Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally.
Show moreShow less
The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatment column, certified reference, and quality control.
It also provides specialized solutions, which include multi-mode precision detection, project plan for specialized equipment, AI-powered fully automated grain comprehensive testing workstation, digital food safety automatic detection, rapid testing laboratory, smart supervision, and comprehensive solution for rapid testing.
In addition, the company offers software platforms, such as smart grain depot, traceability, orchard, datian, tea garden, and park project, as well as digital village project and agricultural and rural data projects.
Its products are used in dairy, cereal and feed, fruit and vegetable, meat and seafood, honey and egg, laboratory, animal health, and other industries. The company was founded in 2007 and is headquartered in Shenzhen, China.
Stock analysis
Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) currently trades at ¥5.66, while our model-based Fair Value estimate is ¥1.28, 77% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥1.46 per share, and 1 of the 25 models we run sit above the ¥5.66 price.
Bear case: the Earnings-Based group reads lowest at ¥0.4150, and 24 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.8500 (bear) to ¥1.49 (bull), the price of ¥5.66 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Shenzhen Bioeasy Biotechnology Co. Ltd. reported revenue of 263M CNY in FY2025 versus 598M CNY in FY2021, a compound −18.5%/yr. Reported net income was 13.7M CNY in FY2025, compounding −50.9%/yr from FY2021.
Key figures
Market cap 2.4B CNY (≈ $355M) Small · P/S ratio 8.85 · EPS (TTM) ¥−0.0200 · Dividend yield 0.4% · Net margin −3.0% · Return on equity −0.7% · Return on assets (EBIT) 4.2% (5-year average) · Operating margin 0.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −77%, 300942 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.3300 to ¥9.63). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥0.8500Fair Value ¥1.28Bull¥1.49
Price ¥5.66 · Downside -77.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−33.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−33.5%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−33.5% vs −34.5%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 23.0%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+43.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +41.5% a year for the price.
Compare Shenzhen Bioeasy Biotechnology Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−77.9% · Bottom 25%
Profitability
Return on assets0.9% · Above median
Net margin (12 months)−3.0% · Below median
Operating margin (12 months)0.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)18.0% · Above median
Dividend yield (12 months)0.4% · Below median
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥1.28 versus a price of ¥5.66, about 77% lower (overvalued).
What is the fair value of 300942?
Our model-based fair value for Shenzhen Bioeasy Biotechnology Co. Ltd. is ¥1.28 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥5.66.
What is the quality score of 300942?
Shenzhen Bioeasy Biotechnology Co. Ltd. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Our model-based price target is the fair value of ¥1.28 (as of Nov 7, 2026) from 25 valuation models. Cautious scenario ¥0.8500, optimistic scenario ¥1.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Shenzhen Bioeasy Biotechnology Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥1.28, about 77% lower versus a price of ¥5.66 (overvalued). Cautious scenario ¥0.8500, optimistic scenario ¥1.49. The calculation is refreshed regularly with new filings.
What is the revenue of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Shenzhen Bioeasy Biotechnology Co. Ltd. reported trailing-twelve-month revenue of about 282M CNY (latest available figure, as of Nov 7, 2026).
Does Shenzhen Bioeasy Biotechnology Co. Ltd. pay a dividend?
Shenzhen Bioeasy Biotechnology Co. Ltd. currently shows a dividend yield of 0.44% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) and when is the ex-dividend date?
Shenzhen Bioeasy Biotechnology Co. Ltd. pays a dividend of ¥0.025 per share a year, a dividend yield of 0.4%. The last ex-dividend date was Jun 3, 2026. The payout ratio is 73.7% of earnings. Free cash flow covers the dividend 2.07 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
For today's price to be fair in a discounted-cash-flow model, Shenzhen Bioeasy Biotechnology Co. Ltd. would have to grow free cash flow by +43.9 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 300942 use?
Our models discount Shenzhen Bioeasy Biotechnology Co. Ltd. at 10.5 %: a base by market capitalisation (small), damped by beta 0.52, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shenzhen Bioeasy Biotechnology Co. Ltd. that is +43.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) delivered so far?
Over the past 5 years revenue at Shenzhen Bioeasy Biotechnology Co. Ltd. grew +0.4 % a year. The price currently implies free-cash-flow growth of +43.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shenzhen Bioeasy Biotechnology Co. Ltd. (+43.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The free-cash-flow yield on the price is 0.91 %: that much free cash flow Shenzhen Bioeasy Biotechnology Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Bioeasy Biotechnology Co. Ltd. it is ¥1.28 per share (as of Nov 7, 2026), against a price of ¥5.66. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shenzhen Bioeasy Biotechnology Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300942 trades above its calculated fair value: price ¥5.66, fair value ¥1.28, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300942?
No. The price is what the market pays today (¥5.66); the fair value is what the company's own numbers justify (¥1.28). For Shenzhen Bioeasy Biotechnology Co. Ltd. the two are ¥4.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shenzhen Bioeasy Biotechnology Co. Ltd. worth?
The market values Shenzhen Bioeasy Biotechnology Co. Ltd. at about 2.4B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥5.66; our models calculate a fair value of ¥1.28 per share.
What do the bullish and bearish scenarios say about 300942?
Our models span a range for Shenzhen Bioeasy Biotechnology Co. Ltd.: cautious scenario ¥0.8500, base ¥1.28, optimistic ¥1.49 per share (as of Nov 7, 2026, price ¥5.66). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Balance-sheet figures for Shenzhen Bioeasy Biotechnology Co. Ltd. (as of Nov 7, 2026): return on equity −0.7%, debt of 0.46 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 300942 from its 52-week high?
Shenzhen Bioeasy Biotechnology Co. Ltd. trades at ¥5.66, about 49% below its 52-week high of ¥11.07 and at the low of ¥5.66 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.28 is for.
Which stocks are comparable to Shenzhen Bioeasy Biotechnology Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shenzhen Bioeasy Biotechnology Co. Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price ¥5.66, calculated fair value ¥1.28 (−77%), Quality Score 55/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300942 calculated?
We run Shenzhen Bioeasy Biotechnology Co. Ltd. through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥1.28 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shenzhen Bioeasy Biotechnology Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The closing price on Nov 9, 2026 was ¥5.66. Our model-based fair value is ¥1.28, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shenzhen Bioeasy Biotechnology Co. Ltd. right now?
The price sits above even our optimistic bull case (¥1.49). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shenzhen Bioeasy Biotechnology Co. Ltd.
How large is the market capitalisation of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The market capitalisation of Shenzhen Bioeasy Biotechnology Co. Ltd. is 2.4B CNY (≈ $355M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The price-to-sales ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. is 8.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Earnings per share at Shenzhen Bioeasy Biotechnology Co. Ltd. are ¥−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The dividend yield of Shenzhen Bioeasy Biotechnology Co. Ltd. is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The net margin of Shenzhen Bioeasy Biotechnology Co. Ltd. is −3.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The return on equity (ROE) of Shenzhen Bioeasy Biotechnology Co. Ltd. is −0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
On an EBIT basis the return on assets of Shenzhen Bioeasy Biotechnology Co. Ltd. is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
The operating margin of Shenzhen Bioeasy Biotechnology Co. Ltd. is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Revenue at Shenzhen Bioeasy Biotechnology Co. Ltd. is growing +18.0% versus a year earlier (3y avg −27.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shenzhen Bioeasy Biotechnology Co. Ltd. (300942)?
Earnings per share at Shenzhen Bioeasy Biotechnology Co. Ltd. are growing +193% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) carry?
The net debt of Shenzhen Bioeasy Biotechnology Co. Ltd. is 41.2M CNY (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shenzhen Bioeasy Biotechnology Co. Ltd. in the live analysis
One click puts Shenzhen Bioeasy Biotechnology Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026